Does the media favor TLRY or UNCY?

In the previous week, Tilray Brands had 13 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 7 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.76 beat Tilray Brands' score of 0.64 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 8 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer UNCY or OVID?

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.76 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is UNCY or CTNM more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Contineum Therapeutics N/A -24.73% -23.51%

Does the media refer more to UNCY or CTNM?

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 6 mentions for Contineum Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.76 beat Contineum Therapeutics' score of 0.49 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Contineum Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AQST or UNCY?

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 7 mentions for Unicycive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.80 beat Unicycive Therapeutics' score of 0.76 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to UNCY or EOLS?

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Evolus. Evolus' average media sentiment score of 1.04 beat Unicycive Therapeutics' score of 0.76 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Unicycive Therapeutics (UNCY) Competitors

$5.63 +0.18 (+3.30%)

As of 08/21/2026 04:00 PM Eastern

Compare

UNCY vs. TLRY, OVID, CTNM, AQST, and EOLS

Should you buy Unicycive Therapeutics stock or one of its competitors? Unicycive Therapeutics's main competitors and comparable companies include Tilray Brands (TLRY), Ovid Therapeutics (OVID), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), and Evolus (EOLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Unicycive Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Tilray Brands has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Unicycive Therapeutics has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.72	-$121.40M	-$1.08	N/A
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

In the previous week, Tilray Brands had 13 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 7 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.76 beat Tilray Brands' score of 0.64 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	8 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tilray Brands currently has a consensus target price of $11.00, suggesting a potential upside of 127.27%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 233.04%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Unicycive Therapeutics beats Tilray Brands on 10 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Ovid Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A
Ovid Therapeutics	$7.25M	75.43	-$17.41M	-$0.31	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.76 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 233.04%. Ovid Therapeutics has a consensus target price of $5.71, indicating a potential upside of 104.08%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Ovid Therapeutics beats Unicycive Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Unicycive Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A
Contineum Therapeutics	$50M	12.93	-$59.98M	-$1.73	N/A

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Unicycive Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 233.04%. Contineum Therapeutics has a consensus price target of $20.25, indicating a potential upside of 17.80%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Contineum Therapeutics' return on equity of -24.73% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Contineum Therapeutics	N/A	-24.73%	-23.51%

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 6 mentions for Contineum Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.76 beat Contineum Therapeutics' score of 0.49 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Contineum Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Unicycive Therapeutics beats Contineum Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Aquestive Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 82.40%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 233.04%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Unicycive Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	13.13	-$83.78M	-$0.65	N/A
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 7 mentions for Unicycive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.80 beat Unicycive Therapeutics' score of 0.76 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Aquestive Therapeutics beats Unicycive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Evolus?

Unicycive Therapeutics (NASDAQ:UNCY) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Unicycive Therapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A
Evolus	$297.18M	1.86	-$51.64M	-$0.52	N/A

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Evolus	-10.85%	N/A	-13.00%

Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Evolus has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Evolus. Evolus' average media sentiment score of 1.04 beat Unicycive Therapeutics' score of 0.76 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 233.04%. Evolus has a consensus price target of $14.50, indicating a potential upside of 72.82%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Unicycive Therapeutics beats Evolus on 10 of the 16 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$156.82M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-3.22	789.80	272.60	24.24
Price / Sales	230.58	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	2.95	11.89	13.05	6.20
Net Income	-$26.56M	$2.81B	$3.47B	$348.59M
7 Day Performance	2.18%	1.77%	2.09%	0.08%
1 Month Performance	3.11%	3.85%	6.64%	3.88%
1 Year Performance	34.05%	6.56%	25.02%	16.98%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	3.23 of 5 stars	$5.63 +3.3%	$18.75 +233.0%	+34.0%	$156.82M	$680K	N/A	9	Analyst Upgrade
TLRY Tilray Brands	3.8063 of 5 stars	$4.56 +1.7%	$11.00 +141.5%	-57.9%	$622.73M	$210.48M	N/A	3,595
OVID Ovid Therapeutics	2.3227 of 5 stars	$2.84 -1.9%	$5.71 +101.6%	+171.8%	$553.68M	$7.25M	N/A	60
CTNM Contineum Therapeutics	1.144 of 5 stars	$14.62 +0.6%	$20.25 +38.5%	+72.9%	$552.07M	$50M	N/A	31	News Coverage Analyst Upgrade
AQST Aquestive Therapeutics	2.1197 of 5 stars	$4.37 +1.7%	$8.50 +94.7%	+17.1%	$547.86M	$54.09M	N/A	160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. TLRY, OVID, CTNM, AQST, and EOLS

How does Unicycive Therapeutics compare to Tilray Brands?

Summary

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Summary

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Summary

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Summary

How does Unicycive Therapeutics compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. TLRY, OVID, CTNM, AQST, and EOLS

How does Unicycive Therapeutics compare to Tilray Brands?

Which has more risk and volatility, TLRY or UNCY?

Which has stronger earnings & valuation, TLRY or UNCY?

Is TLRY or UNCY more profitable?

Does the media favor TLRY or UNCY?

Do institutionals and insiders hold more shares of TLRY or UNCY?

Do analysts prefer TLRY or UNCY?

Summary

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Which has preferable valuation & earnings, UNCY or OVID?

Is UNCY or OVID more profitable?

Which has more volatility and risk, UNCY or OVID?

Do institutionals & insiders have more ownership in UNCY or OVID?

Does the media prefer UNCY or OVID?

Do analysts prefer UNCY or OVID?

Summary

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Which has preferable valuation and earnings, UNCY or CTNM?

Which has more volatility and risk, UNCY or CTNM?

Do analysts rate UNCY or CTNM?

Do institutionals and insiders have more ownership in UNCY or CTNM?

Is UNCY or CTNM more profitable?

Does the media refer more to UNCY or CTNM?

Summary

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Do analysts recommend AQST or UNCY?

Which has more volatility & risk, AQST or UNCY?

Do insiders and institutionals believe in AQST or UNCY?

Which has preferable earnings & valuation, AQST or UNCY?

Is AQST or UNCY more profitable?

Does the media favor AQST or UNCY?

Summary

How does Unicycive Therapeutics compare to Evolus?

Which has better valuation and earnings, UNCY or EOLS?

Do insiders & institutionals believe in UNCY or EOLS?

Is UNCY or EOLS more profitable?

Which has more risk & volatility, UNCY or EOLS?

Does the media refer more to UNCY or EOLS?

Do analysts prefer UNCY or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools